Dyne Therapeutics

Dyne Therapeutics is a clinical-stage company focused on advancing life-transforming therapeutics for patients with genetically driven neuromuscular diseases. The company employs its proprietary FORCE™ platform, aimed at delivering therapies to muscle and the central nervous system (CNS), with the clear goal of stopping or reversing disease progression. This commitment is reflected in their pipeline, which encompasses various novel treatments for serious conditions such as myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD). Dyne Therapeutics believes in the importance of addressing the significant unmet medical need within these communities by ensuring that their innovative therapies maximize both efficacy and safety.

The company operates with a strong mission to fundamentally change the trajectory of diseases that profoundly impact patients’ lives. With an exceptional team of experts from various backgrounds in drug development and patient care, Dyne Therapeutics nurtures a culture that values collaboration, accountability, and fearless innovation. Their leadership team comprises industry veterans dedicated to their vision of providing hope to patients through groundbreaking therapies. Alongside this, Dyne Therapeutics actively promotes corporate responsibility, emphasizing environmental sustainability, employee well-being, and community engagement. By leveraging its resources effectively and engaging with stakeholders, the company aspires to not just develop drugs, but to make a meaningful impact on the quality of life for patients worldwide.